CN1823766A - Compound amino acid vitamin dispersion tablet and its preparation method - Google Patents

Compound amino acid vitamin dispersion tablet and its preparation method Download PDF

Info

Publication number
CN1823766A
CN1823766A CN 200610066088 CN200610066088A CN1823766A CN 1823766 A CN1823766 A CN 1823766A CN 200610066088 CN200610066088 CN 200610066088 CN 200610066088 A CN200610066088 A CN 200610066088A CN 1823766 A CN1823766 A CN 1823766A
Authority
CN
China
Prior art keywords
vitamin
povidone
usp
sodium
alcoholic solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200610066088
Other languages
Chinese (zh)
Other versions
CN100364528C (en
Inventor
刘毅琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Zhengdong Pharmaceutical Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2006100660882A priority Critical patent/CN100364528C/en
Publication of CN1823766A publication Critical patent/CN1823766A/en
Application granted granted Critical
Publication of CN100364528C publication Critical patent/CN100364528C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A dispersing tablet of compound amino acid-vitamin for treating throat disease and hypoproteinemia contains 11 amino acids including L-isoleucine, L-leucine, L-lysine hydrochloride, etc, 6 vitamins including VB1 nitrate, VB2, VB6, etc, cross-linked carboxymethyl cellulose sodium carboxymethyl starch sodium and microcrystalline cellulose. Its preparing process is also disclosed.

Description

A kind of compound amino acid vitamin dispersion tablet and preparation method thereof
Technical field
The present invention relates to compound amino acid vitamin dispersion tablet of a kind of auxiliary treatment that is used for hypoproteinemia etc. and preparation method thereof, belong to field of pharmaceutical preparations.
Background technology
Aminoacid is to constitute proteinic ultimate unit, also is crucial nutritional labeling.In vivo, aminoacid generates 2-ketoacid through deamination except being used for synthetic tissue albumen, and further oxidation energy supply changes saccharide and fat into.Aminoacid also can be used as the substrate of glucose, the carrier of nitrogen in addition, participates in the adjusting of enzymatic activity and ion channel simultaneously.
Protein in the food must be through intestines and stomach digestion, resolves into aminoacid utilizations that just can be absorbed by the body, and human body be exactly to amino acid whose needs to proteinic needs reality.Aminoacid after the absorption only can both satisfy the human body needs on value volume and range of product, health could utilize them to synthesize the protein of self.The threpsology is last to be divided into essential amino acids and non essential amino acid two classes with aminoacid.Essential amino acids refers to that human body self can not synthesize or aggregate velocity can not satisfy the human body needs, the aminoacid that must absorb from food.Concerning the adult, this amino acid has 8 kinds, comprises lysine, methionine, leucine, isoleucine, threonine, valine, tryptophan and phenylalanine.Concerning the baby, histidine also is an essential amino acids.Non essential amino acid is not that human body does not need these aminoacid, but says that human body can self be synthetic or transformed and obtained by other aminoacid, not necessarily must be from the direct picked-up of food, and glutamic acid, arginine, glycine all belong to this amino acid.Valine, isoleucine, leucine, arginine have the liver function of improvement, suppress myogen decomposes, and improves immunity, urea circulation activation, the generation of tired material 5-hydroxy tryptamine in the brain is had pharmacological actions such as inhibitory action; Also there is the report arginine to have the effect that promotes hormone secretion and enhancing immunity.
The aminoacid clinical application is extensive, and for example: the 1. application of hepatic disease: to acute, that evil is acute and chronic hepatitis gravis causes hepatic coma, liver cirrhosis, the ascites that hepatic ascites especially hepatocarcinoma is caused has diuresis.2. the application of kidney disease: have and alleviate uremia's symptom, correct azotemia, reduce serium inorganic phosphorus and increase the effect of Abwehrkraft des Koepers, be mainly used in non-eventually terminal phase chronic renal failure patients, especially be negative nitrogen balance and low protein diet can not rectifier.3. the assistance application of cancer chemotherapy: test shows with clinical research, and the uneven amino acid transfusion that lacks sulfur-containing amino acid can make tumor cell generation proteinaceous nutrient defective and be suppressed, thereby improves the therapeutic effect of anticancer chemotherapeutic agent.4. the auxiliary treatment of intestinal tract disease: 8 kinds of essential amino acids do not need or can absorb through digestion slightly, can supply oral or tube feed, be applicable to and swallow but still have the patient of digestive and absorptive functions to improve nutritional status, promote wound healing, enhancing immunity and tolerance to treating, especially to diseases such as rectal cancer, it is more suitable that postoperative is used.5. the treatment of large-area burns: branched-chain amino acid (BCAA) concentration lowers and aromatic amino acid (AAA) concentration raises is the most outstanding change in the burn serum aminoacid collection of illustrative plates, treat burn patients with 14AA-800, make BCAA remain on normal range, the ratio of BCAA/AAA promotes protein synthesis near normal.
Vitamin medicaments just to safeguarding that human health has played important function, therefore has been called again " vitamin " since coming out.Wherein vitamin B group absorbs by liver, but has greatly because of not absorbing along with urine excretes, so vitamin B group content and few in the human body, often needs additional.Lack vitamin B group in the human body and can cause cell tissue depletion, pathological changes, aging, finally can cause death.
Vitamin B1 is a kind of cell energy that can promote the muscular tissue g and D.It can improve people's intelligence and muscle power, and has Detoxication; It is the important component part of coenzyme, plays an important role in carbohydrate is converted into the process of energy.Lack it and can cause beriberi syndrome and Wei Erni card disease (nervous system disease).Vitamin B2 is the ingredient of rhodopsin, can protect retina to avoid the injury of ultraviolet radiation, also has the antioxidative effect, can repair epithelial tissue and mucosa, participates in the metabolism of oxidoreduction and fat, protein and carbohydrate.Clinical being mainly used in prevented and treated angular cheilitis, glossitis, scrotitis, conjunctivitis, seborrheic dermatitis.Find again that in addition vitamin B2 has multiple new purposes: can treat migraine, may be the energy potential that it has improved cell mitochondrial; Have good anticoagulation, can improve myocardial ischemia and dwindle the myocardial ischemia scope, be used for the treatment of cardiovascular and cerebrovascular disease; The carcinogenesis that suppresses chemical substance azobenzene (being called for short DAB) material is arranged.The adult shows as on eyes, nose and the mouth skin on every side and oils and fats, squama seborrheic dermatitis occur during Vitamin B6 deficiency, and other parts to health spread subsequently; Red tongue is smooth; Weight loss, muscle weakness, irritability, spirit depressing; The baby shows as neural irritable, muscle twitches and convulsions.Vitamin B6 can be treated primary dysmenorrhea, and is without any side effects; Can galactopoiesis, mechanism may be the generation that promotes dopamine in the brain, thereby impels dopamine receptor to cause that secondary feedback reduces the pituitary gland prolactin secretion, and then suppresses galactopoiesis.Nicotiamide (vitamin B3) can reduce by accelerating oxidation, helps fat and carbohydrate to be converted into energy, and the fatty gruel type in vasodilator and the preclude blood also plays an important role to regulating thyroid and epinephrine function.In addition, nicotiamide can strengthen sinus node function, promotes the chamber conduction, reduces myocardial excitability; Can also stop alloxan or Streptozocin to destroy beta Cell of islet, strengthen the β cell, stop the generation of diabetes causing the resistance of damage factor.Be used for sick sinus syndrome, atrioventricular block clinically, the treatment insulin dependent diabetes mellitus (IDDM).Folic acid (vitamin B 9) is a kind of vitamin B group that human erythrocyte is reached maturity and helped out, be mainly used in and prevent and treat megaloblastic anemia, in addition cardiovascular and cerebrovascular vessel, tumor, neonate neural tube defects and senile mental sickness are also had certain curative effect.Vitamin E can be protected polyvalent unsaturated fatty acid to avoid oxidation and destroy, and keeps biomembranous normal configuration.The peroxidization that can also block unsaturated fatty acid, reduce the generation of lipid peroxide, energy is regulated mitochondrial respiration rate and is influenced the content of line grain cylinder cell pigment, also can suppress lipopolysaccharide cause GMGS excretory-MDA of OH and secondary thereof gathers, the secretion and the MDA that suppress mesangial cell-OH gather, promote apoptosis, and can suppress the paraplasm of mesangial cell.Clinical application is extensive, and excellent usage is all being arranged aspect cardiovascular disease, disease in the blood system, the cutaneous diseases.
Because aminoacid and vitamin are extremely important to keeping health, suitably replenish the immunity that can effectively improve human body.In addition, under some pathological conditions, for example chronic hepatopathy, liver cirrhosis or nephropathy, and surgical operation such as burn, fracture or malignant tumor all may cause negative nitrogen balance and hypoproteinemia, except Drug therapy, replenish aminoacid and vitamin and also can the recovery of disease be played an important role at concrete disease.
The compound recipe ammonia dimension capsule of selling in the market is a kind of effective preparation in this field, but because effective ingredient wherein, for example the water solublity of tryptophan, phenylalanine, vitamin B2, folic acid etc. is very poor, has influenced absorption, has also limited said preparation popularization and use clinically.
Summary of the invention
Therefore, people still wish to develop a kind of good absorbing, rapid-action amino acid, vitamine supplementing preparation.The inventor utilizes modern science and technology, through secular screening and experiment, finally succeeded in developing a kind of amino acid, vitamine supplement---compound amino acid vitamin dispersion tablet of novel form, it is the bioavailability height not only, not only can swallow but also can drop in the water and take after the dispersion simultaneously, be convenient to the patient and take medicine, especially be fit to old, children and the ailing patient of throat and take, expanded the scope of application greatly.
Purpose of the present invention is exactly that a kind of good absorbing, rapid-action compound amino acid vitamin dispersion tablet will be provided.
Another object of the present invention provides the preparation method of this dispersible tablet.
Compound amino acid vitamin dispersion tablet of the present invention contains 11 seed amino acids such as L-isoleucine, L-leucine, L-lysine hydrochloride, L-phenylalanine, L-threonine, L-valine, L-tryptophan, L-methionine, L-arginine hydrochloride, L-glutamic acid and glycine, six kinds of vitamin such as vitamin b1 nitrate, vitamin B2, vitamin B6, vitamin E, nicotiamide and folic acid, and adjuvant such as cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, microcrystalline Cellulose.This dispersible tablet at first enters liver mainly in little intestinal absorption after the absorption, a part participates in protein synthesis, and another part enters blood, replenishes the serum amino acid pond, improves the serum amino acid spectrum, and then is that tissue utilizes or transform metabolism.Therefore, dispersible tablet of the present invention not only can be used to improve body immunity, and can be used for the auxiliary treatment of the hypoproteinemia that various diseases causes, as the hypoproteinemia due to chronic hepatopathy, liver cirrhosis or the nephropathy, and due to surgical postoperative or the malignant tumor negative nitrogen balance and hypoproteinemia the nutritional supplementation treatment.
Compound amino acid vitamin dispersion tablet of the present invention is white and orange double-layer tablet, and in 1000, wherein white tablets contains: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 10--80g, carboxymethyl starch sodium 5--40g, microcrystalline Cellulose 50--300g, sodium lauryl sulphate 1--20g, micropowder silica gel 1--20g, magnesium stearate 1--10g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of; Orange contains: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B6 (C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 10-80g, carboxymethyl starch sodium 5--40g, microcrystalline Cellulose 50--300g, sodium lauryl sulphate 0.1--10g, micropowder silica gel 0.1--10g, magnesium stearate 0.1--10g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of.
Dispersible tablet of the present invention can prepare with following method:
1. raw material (except that vitamin E) was pulverized the 80--120 mesh sieve, adjuvant was pulverized the 80--120 mesh sieve; 30 POVIDONE K 30 BP/USP 30 is made the alcoholic solution of 2-10%, and is standby;
2. with cross-linking sodium carboxymethyl cellulose, the microcrystalline Cellulose mixing of amino acid starting material with the white tablets recipe quantity, with 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution system soft materials, granulate with 20 mesh sieves, 50-55 ℃ of drying, behind the 18 mesh sieve granulate, add carboxymethyl starch sodium, sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
3. with cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, the microcrystalline Cellulose mixing of vitamin raw materials with orange tablet recipe amount, vitamin E is with 2-10% 30 POVIDONE K 30 BP/USP 30 dissolve with ethanol solutions of half amount, join in the supplementary material mixture, mixing with 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution system soft materials, is granulated with 20 mesh sieves then, 50-55 ℃ of drying, behind the 18 mesh sieve granulate, add sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
4. press double-layer tablet, promptly.
Dispersible tablet of the present invention is compared with conventional capsule, and need 9-12 minute average disintegration of capsule, and dispersible tablet of the present invention can disintegrate fully in 1 minute, makes bioavailability improve greatly.Dispersible tablet not only can be swallowed but also can drop in the water and take after the dispersion simultaneously, be convenient to the patient and take medicine, especially be fit to old, children and the ailing patient of throat and take, and easy to carry, can satisfy requirement of different patients, have clinical application and good market prospect very widely.In addition, be pressed into double-layer tablet after aminoacid and vitamin granulated respectively, also avoided the interaction between the two well, guaranteed curative effect.
The specific embodiment
Come further to set forth dispersible tablet of the present invention and preparation method thereof by the following examples.
[embodiment 1]
The white tablets prescription is: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 40g, carboxymethyl starch sodium 20g, microcrystalline Cellulose 160g, sodium lauryl sulphate 6g, micropowder silica gel 6g, magnesium stearate 3g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of;
Orange tablet recipe is: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B6 (C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 30g, carboxymethyl starch sodium 20g, microcrystalline Cellulose 130g, sodium lauryl sulphate 3g, micropowder silica gel 3g, magnesium stearate 2g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of;
After getting the raw materials ready by above-mentioned prescription, adopt following prepared:
1. raw material (except that vitamin E) was pulverized 120 mesh sieves, adjuvant was pulverized 120 mesh sieves; 30 POVIDONE K 30 BP/USP 30 is made 10% alcoholic solution, and is standby;
2. with cross-linking sodium carboxymethyl cellulose, the microcrystalline Cellulose mixing of amino acid starting material with the white tablets recipe quantity, with 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, granulate with 20 mesh sieves, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add carboxymethyl starch sodium, sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
3. with cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, the microcrystalline Cellulose mixing of vitamin raw materials with orange tablet recipe amount, vitamin E is with 10% 30 POVIDONE K 30 BP/USP, 30 dissolve with ethanol solutions of half amount, join in the supplementary material mixture, mixing with 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, is granulated with 20 mesh sieves then, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
4. press double-layer tablet.
[embodiment 2]
The white tablets prescription is: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 10g, carboxymethyl starch sodium 5g, microcrystalline Cellulose 50g, sodium lauryl sulphate 2g, micropowder silica gel 2g, magnesium stearate 1g, 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution are an amount of;
Orange tablet recipe is: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B6 (C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 20g, carboxymethyl starch sodium 15g, microcrystalline Cellulose 70g, sodium lauryl sulphate 2g, micropowder silica gel 2g, magnesium stearate 1g, 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution are an amount of;
After getting the raw materials ready by above-mentioned prescription, adopt following prepared:
1. raw material (except that vitamin E) was pulverized 80 mesh sieves, adjuvant was pulverized 80 mesh sieves; 30 POVIDONE K 30 BP/USP 30 is made 5% alcoholic solution, and is standby;
2. with cross-linking sodium carboxymethyl cellulose, the microcrystalline Cellulose mixing of amino acid starting material with the white tablets recipe quantity, with 5% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, granulate with 20 mesh sieves, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add carboxymethyl starch sodium, sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
3. with cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, the microcrystalline Cellulose mixing of vitamin raw materials with orange tablet recipe amount, vitamin E is with 5% 30 POVIDONE K 30 BP/USP, 30 dissolve with ethanol solutions of half amount, join in the supplementary material mixture, mixing with 5% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, is granulated with 20 mesh sieves then, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
4. press double-layer tablet.
[embodiment 3]
The white tablets prescription is: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 80g, carboxymethyl starch sodium 40g, microcrystalline Cellulose 300g, sodium lauryl sulphate 12g, micropowder silica gel 12g, magnesium stearate 6g, 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution are an amount of;
Orange tablet recipe is: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B6 (C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 60g, carboxymethyl starch sodium 40g, microcrystalline Cellulose 250g, sodium lauryl sulphate 6g, micropowder silica gel 6g, magnesium stearate 4g, 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution are an amount of;
After getting the raw materials ready by above-mentioned prescription, prepare in order to the below method:
1. raw material (except that vitamin E) was pulverized 100 mesh sieves, adjuvant was pulverized 100 mesh sieves; 30 POVIDONE K 30 BP/USP 30 is made 10% alcoholic solution, and is standby;
2. with cross-linking sodium carboxymethyl cellulose, the microcrystalline Cellulose mixing of amino acid starting material with the white tablets recipe quantity, with 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, granulate with 20 mesh sieves, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add carboxymethyl starch sodium, sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
3. with cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, the microcrystalline Cellulose mixing of vitamin raw materials with orange tablet recipe amount, vitamin E is with 10% 30 POVIDONE K 30 BP/USP, 30 dissolve with ethanol solutions of half amount, join in the supplementary material mixture, mixing with 10% 30 POVIDONE K 30 BP/USP, 30 alcoholic solution system soft materials, is granulated with 20 mesh sieves then, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
4. press double-layer tablet.

Claims (3)

1. a compound amino acid vitamin dispersion tablet is characterized in that it is white and orange double-layer tablet, and in 1000, wherein white tablets contains: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 10--80g, carboxymethyl starch sodium 5--40g, microcrystalline Cellulose 50--300g, sodium lauryl sulphate 1--20g, micropowder silica gel 1--20g, magnesium stearate 1--10g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of; Orange contains: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B 6(C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 10-80g, carboxymethyl starch sodium 5--40g, microcrystalline Cellulose 50--300g, sodium lauryl sulphate 0.1--10g, micropowder silica gel 0.1--10g, magnesium stearate 0.1--10g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of.
2. compound amino acid vitamin dispersion tablet as claimed in claim 1 is characterized in that wherein white tablets contains in 1000: isoleucine (C 6H 13NO 2) 18.0g, leucine (C 6H 13NO 2) 10.0g, lysine hydrochloride (C 6H 14N 2O 2HCl) 21.75g, phenylalanine (C 9H 11NO 2) 7.5g, threonine (C 4H 9NO 3) 4.0g, valine (C 5H 11NO 2) 6.0g, tryptophan (C 11H 12N 2O 2) 5.0g, methionine (C 15H 11NO 2S) 18.0g, arginine hydrochloride (C 6H 14N 4O 2HCl) 10.0g, glutamic acid (C 5H 9NO 4) 15.0g, glycine (C 2H 5NO 2) 25.0g, cross-linking sodium carboxymethyl cellulose 40g, carboxymethyl starch sodium 20g, microcrystalline Cellulose 160g, sodium lauryl sulphate 6g, micropowder silica gel 6g, magnesium stearate 3g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of; Orange contains: vitamin B 1Nitrate (C 12H 17ClN 4OSHNO 3) 7.5g, vitamin B 2(C 17H 20N 4O 6) 2.5g, vitamin B 6(C 8H 11N 30HCl) 7.0g, vitamin E (C 31H 52O 3) 2.0g, nicotiamide (C 6H 6N 2O) 15.0g, folic acid (C 19H 19N 7O 6) 0.5g, cross-linking sodium carboxymethyl cellulose 30g, carboxymethyl starch sodium 20g, microcrystalline Cellulose 130g, sodium lauryl sulphate 3g, micropowder silica gel 3g, magnesium stearate 2g, 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution are an amount of.
3. the preparation method of claim 1 or 2 described compound amino acid vitamin dispersion tablets is characterized in that it may further comprise the steps:
1. aminoacid and vitamin raw materials except that vitamin E were pulverized the 80--120 mesh sieve, all the other adjuvants were pulverized the 80--120 mesh sieve, and 30 POVIDONE K 30 BP/USP 30 is made the alcoholic solution of 2-10%, and is standby;
2. with cross-linking sodium carboxymethyl cellulose, the microcrystalline Cellulose mixing of amino acid starting material with white tablets institute content, with 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution system soft materials, granulate with 20 mesh sieves, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add carboxymethyl starch sodium, sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
3. with cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, the microcrystalline Cellulose mixing of vitamin raw materials with orange institute's content, vitamin E is with 2-10% 30 POVIDONE K 30 BP/USP 30 dissolve with ethanol solutions of half amount, join in the supplementary material mixture, mixing with 2-10% 30 POVIDONE K 30 BP/USP 30 alcoholic solution system soft materials, is granulated with 20 mesh sieves then, 55 ℃ of dryings, behind the 18 mesh sieve granulate, add sodium lauryl sulphate, micropowder silica gel and magnesium stearate, mixing;
4. press double-layer tablet, promptly.
CNB2006100660882A 2006-03-30 2006-03-30 Compound amino acid vitamin dispersion tablet and its preparation method Active CN100364528C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100660882A CN100364528C (en) 2006-03-30 2006-03-30 Compound amino acid vitamin dispersion tablet and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100660882A CN100364528C (en) 2006-03-30 2006-03-30 Compound amino acid vitamin dispersion tablet and its preparation method

Publications (2)

Publication Number Publication Date
CN1823766A true CN1823766A (en) 2006-08-30
CN100364528C CN100364528C (en) 2008-01-30

Family

ID=36934709

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100660882A Active CN100364528C (en) 2006-03-30 2006-03-30 Compound amino acid vitamin dispersion tablet and its preparation method

Country Status (1)

Country Link
CN (1) CN100364528C (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102784147A (en) * 2011-05-19 2012-11-21 金色年华药业有限公司 Compound amino acid vitamin capsule
CN108740361A (en) * 2018-04-26 2018-11-06 江西派尼生物药业有限公司 A kind of coating multi-vitamins and the preparation method and application thereof
CN108785250A (en) * 2017-08-10 2018-11-13 安徽农业大学 A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure
CN108815150A (en) * 2017-08-10 2018-11-16 安徽农业大学 It is a kind of to treat dog cat acute and chronic renal failure compound amino acid piece and preparation method thereof
CN113181131A (en) * 2020-06-11 2021-07-30 许新朋 Novel drug formula for immunotherapy and tablet structure thereof
CN114099516A (en) * 2020-09-01 2022-03-01 河北科星药业有限公司 Compound amino acid solution for animals and preparation method and application thereof
CN114980877A (en) * 2020-01-13 2022-08-30 专业营养股份公司 Composition comprising amino acids for preventing and/or treating cancer
CN115040521A (en) * 2022-05-10 2022-09-13 金陵科技学院 Application of B vitamins and butyrate composition in preparation of medicine for killing gastric cancer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507862A (en) * 2002-12-19 2004-06-30 洁 严 Complex acetaminophen vitamin C dispersion tablet and preparing method thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102784147A (en) * 2011-05-19 2012-11-21 金色年华药业有限公司 Compound amino acid vitamin capsule
CN108785250A (en) * 2017-08-10 2018-11-13 安徽农业大学 A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure
CN108815150A (en) * 2017-08-10 2018-11-16 安徽农业大学 It is a kind of to treat dog cat acute and chronic renal failure compound amino acid piece and preparation method thereof
CN108740361A (en) * 2018-04-26 2018-11-06 江西派尼生物药业有限公司 A kind of coating multi-vitamins and the preparation method and application thereof
CN108740361B (en) * 2018-04-26 2022-06-28 江西派尼生物药业有限公司 Coated multivitamin and preparation method and application thereof
CN114980877A (en) * 2020-01-13 2022-08-30 专业营养股份公司 Composition comprising amino acids for preventing and/or treating cancer
CN113181131A (en) * 2020-06-11 2021-07-30 许新朋 Novel drug formula for immunotherapy and tablet structure thereof
WO2021249286A1 (en) * 2020-06-11 2021-12-16 许新朋 New drug formula for immunotherapy and tablet structure thereof
CN114099516A (en) * 2020-09-01 2022-03-01 河北科星药业有限公司 Compound amino acid solution for animals and preparation method and application thereof
WO2022047840A1 (en) * 2020-09-01 2022-03-10 河北科星药业有限公司 Compound amino acid solution for animal, preparation method therefor, and application thereof
CN115040521A (en) * 2022-05-10 2022-09-13 金陵科技学院 Application of B vitamins and butyrate composition in preparation of medicine for killing gastric cancer cells
CN115040521B (en) * 2022-05-10 2023-09-22 金陵科技学院 Application of B-vitamin and butyrate composition in preparation of medicines for killing gastric cancer cells

Also Published As

Publication number Publication date
CN100364528C (en) 2008-01-30

Similar Documents

Publication Publication Date Title
CN100364528C (en) Compound amino acid vitamin dispersion tablet and its preparation method
AU2022205198B2 (en) Modified release orally administered amino acid formulations
CN1756543A (en) Inhibitor for liver cancer onset and progress
TW202025997A (en) Methods of normalizing amino acid metabolism
KR20180028539A (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
JPS643847B2 (en)
CN101773512B (en) 8-amino acid/11-vitamin containing micro granule capsule and preparation method thereof
CN107468705A (en) A kind of compound electrolyte glucose injection and preparation method thereof
JP2534139B2 (en) Oral amino acid preparation for renal failure
CN102755310B (en) A kind of composition medicine preparation containing levodopa
JPH04159219A (en) Oral amino acid preparation for renal insufficiency
CN1640396A (en) Novel medicinal compositions
CN107951875A (en) A kind of composite preparation containing levodopa
US7572832B2 (en) Non-hygroscopic L-carnitine salts
JP5114394B2 (en) Medicine for fatigue recovery
JP2618653B2 (en) Amino acid preparations for patients with hepatic encephalopathy
CN113116898A (en) Composition containing levocarnitine or acetyl levocarnitine and yohimbine with weight losing function and application thereof
CN1679614A (en) Medicinal composition for treating viral hepatitis, hepatocirrhosis and congestive cardiac failure
CN114246856A (en) Composition containing amino acid derivative
CN118871096A (en) Pharmaceutical composition and medicament comprising L-tryptophan, L-5-hydroxytryptophan and a peripheral degradation inhibitor
KR20240152875A (en) Pharmaceutical compositions and agents comprising L-tryptophan, L-5-hydroxytryptophan and a peripheral glycolytic inhibitor
BR112018005943B1 (en) ORAL ADMINISTRATION AMINO ACIDS FORMULATIONS WITH MODIFIED RELEASE
JPH06305963A (en) Improving agent for fatigue
CN1634126A (en) Medicine of polysaccharide sulfate amino acid salt, its preparation and application
CN101062047A (en) Combination including isoglycyrrhizinate and oxymatrine and the purpose thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200707

Address after: No.8, Yinger Road, mashangshan, Wuxi, Jiangsu Province, 214092

Patentee after: Wuxi Zhengdong Pharmaceutical Co.,Ltd.

Address before: 214091, No. two, No. 8, Ying Mao Road, Mashan Pharmaceutical Industrial Park, Jiangsu, Wuxi

Patentee before: Hu Zhengyue

TR01 Transfer of patent right